Literature DB >> 8224618

Alpha-interferon enhances gamma-interferon production of peripheral blood mononuclear cells pre-activated with phytohemagglutinin.

K Katayama1, N Hayashi, T Takehara, K Suzuki, A Kasahara, H Fusamoto, T Kamada.   

Abstract

The question of whether the state of T cell activation is responsible for gamma-interferon production in response to alpha-interferon was determined. When peripheral blood mononuclear cells were pre-incubated with phytohemagglutinin for 3 days, their gamma-interferon production was found to be augmented by alpha-interferon, accompanied by an increased proportion of DR-positive T cells. This did not occur with fresh cells. The effect was dose-dependent and inhibited by anti-alpha-interferon antibody. Therefore, alpha-interferon was considered to enhance the production of gamma-interferon of pre-activated peripheral blood mononuclear cells but not of resting ones. In conclusion, alpha-interferon augmented the production of gamma-interferon of peripheral blood mononuclear cells only when they had already been activated, suggesting a role of alpha-interferon as a modulator of the cellular immune response.

Mesh:

Substances:

Year:  1993        PMID: 8224618     DOI: 10.1007/bf02806348

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  18 in total

1.  Hepatitis B core antigen-specific IFN-gamma production of peripheral blood mononuclear cells in patients with chronic hepatitis B virus infection.

Authors:  M Inoue; S Kakumu; K Yoshioka; Y Tsutsumi; T Wakita; M Arao
Journal:  J Immunol       Date:  1989-06-01       Impact factor: 5.422

2.  Antigen-specific and -nonspecific mitogenic signals in the activation of human T cell clones.

Authors:  E R Nisbet-Brown; J W Lee; R K Cheung; E W Gelfand
Journal:  J Immunol       Date:  1987-06-01       Impact factor: 5.422

Review 3.  Regulation of cytokine gene expression.

Authors:  T Taniguchi
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

4.  T helper cell subsets require the expression of distinct costimulatory signals by antigen-presenting cells.

Authors:  C T Weaver; C M Hawrylowicz; E R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

5.  Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B.

Authors:  J H Hoofnagle; M Peters; K D Mullen; D B Jones; V Rustgi; A Di Bisceglie; C Hallahan; Y Park; C Meschievitz; E A Jones
Journal:  Gastroenterology       Date:  1988-11       Impact factor: 22.682

6.  Relationship of HLA protein display to activation of 2-5A synthetase in HBe antigen or anti-HBe positive chronic HBV infection.

Authors:  T Ikeda; M Pignatelli; A M Lever; H C Thomas
Journal:  Gut       Date:  1986-12       Impact factor: 23.059

7.  Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial.

Authors:  R P Perrillo; F G Regenstein; M G Peters; K DeSchryver-Kecskemeti; C J Bodicky; C R Campbell; M C Kuhns
Journal:  Ann Intern Med       Date:  1988-07-15       Impact factor: 25.391

8.  Effects of alpha-interferon on gamma-interferon production of peripheral blood mononuclear cells in hepatitis B virus carriers.

Authors:  K Katayama; N Hayashi; T Takehara; T Towata; A Kasahara; H Fusamoto; T Kamada
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

9.  Immune interferon: a pleiotropic lymphokine with multiple effects.

Authors:  G Trinchieri; B Perussia
Journal:  Immunol Today       Date:  1985-04

10.  The significance of alpha/beta interferons and gamma interferon produced in mice infected with Listeria monocytogenes.

Authors:  A Nakane; T Minagawa
Journal:  Cell Immunol       Date:  1984-10-01       Impact factor: 4.868

View more
  1 in total

1.  Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis.

Authors:  M Rotondi; A Oliviero; P Profice; C M Mone; B Biondi; A Del Buono; G Mazziotti; A M Sinisi; A Bellastella; C Carella
Journal:  J Endocrinol Invest       Date:  1998-12       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.